BD (Becton, Dickinson and Company) launched HemoSphere Alta, an advanced hemodynamic monitoring platform with predictive artificial intelligence (AI)-based algorithms to help proactively address blood pressure instability and optimize blood flow.

HemoSphere Alta is the first product launch from the Advanced Patient Monitoring business since BD’s acquisition from Edwards.

It features a Cerebral Autoregulation Index (CAI), a parameter that shows whether the brain is likely to maintain stable blood flow despite blood pressure changes. CAI can be accessed when using a noninvasive ForeSight IQ sensor placed on the patient’s forehead, combined with an Acumen IQ sensor connected to the patient’s arterial line.

The platform also includes the Acumen Hypotension Prediction Index (HPI) software, which predicts when a patient might have a low blood pressure event. BD said this was shown in several studies to reduce the depth, duration, and severity of hypotension.

Dr. Charles Hogue, chairman of the Department of Anesthesiology at Northwestern University Feinberg School of Medicine in Chicago said this is important because research over the past twenty years has shown the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold.

“The availability of the novel Cerebral Autoregulation Index provides clinicians with a tool to detect conditions of impaired autoregulation and can help identify a patient’s lower limit of autoregulation,” Dr. Hogue told the press. “This, in combination with Hypotension Prediction Index technology and other advanced software and algorithms on the HemoSphere Alta platform allows us to both customize and predict patients’ low blood pressure.”

HemoSphere Alta’s new monitor touts a larger 15-inch high-resolution, customizable touchscreen, split-screen views, and a design to minimize disruptive pop-ups. Voice and gesture command features help keep sterility and allow hands-free interaction to silence alarms and switch views.

“HemoSphere Alta marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability,” said Tim Patz, president of BD Advanced Patient Monitoring. “These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients.”